Important: this page is educational. Retatrutide is investigational and is not available by prescription as of this writing.
What is retatrutide?
Retatrutide is a once-weekly investigational peptide that activates three receptors: GLP-1, GIP, and glucagon. It is developed by Eli Lilly and is one of the most closely watched compounds in metabolic medicine. The triple mechanism is the first of its kind to advance into Phase 3 trials.
How does retatrutide work?
The GLP-1 component reduces appetite and slows gastric emptying. The GIP component enhances insulin sensitivity and may improve tolerability. The glucagon component is the novel piece: glucagon receptor agonism increases hepatic fat oxidation and energy expenditure, which appears to compound weight loss and target liver fat directly. The mechanism is conceptually different from semaglutide and tirzepatide, which act only on incretin pathways.
For context on the broader class, read the GLP-1 101 guide.
Phase 2 data
In a 48-week Phase 2 obesity trial published in NEJM in 2023, retatrutide produced placebo-adjusted weight loss of approximately 17 to 24 percent depending on dose. The curve had not yet plateaued at 48 weeks, suggesting peak effect could be even higher with longer treatment. Hemoglobin A1c reductions were comparable to or exceeded current dual agonists. Improvements in liver fat were substantial, with many participants achieving near-complete resolution of hepatic steatosis.
How is retatrutide dosed?
In trials, retatrutide titrates from 2 mg weekly through 4, 8, and 12 mg weekly. The slow ramp manages gastrointestinal tolerability, which appears similar to other GLP-1-based drugs. Final dosing for any future approval is still pending.
How long until retatrutide works?
Trial participants reported appetite changes in the first one to two weeks, similar to other incretin drugs. Weight loss accelerated through week 48 without a clear plateau. Liver fat reductions appeared early and continued.
Side effects of retatrutide
The side-effect profile in Phase 2 resembled the GLP-1 class: nausea, diarrhea, constipation, and decreased appetite. The glucagon component introduces theoretical risks including transient increases in heart rate and small rises in fasting glucose at higher doses, both observed in trials. Long-term safety remains under study.
Who should not take retatrutide?
Outside of clinical trials, no one can be prescribed retatrutide right now. Anticipated contraindications will likely mirror the GLP-1 class: medullary thyroid carcinoma, MEN-2 history, active pancreatitis, severe gastroparesis, pregnancy, and breastfeeding. The glucagon component may add cautions for cardiovascular and glycemic monitoring.
When might retatrutide be available?
Phase 3 trials in obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis are ongoing through 2026. FDA decision timing depends on trial readouts and regulatory review. The most likely earliest approval window is 2027.
Why we are watching it
If Phase 3 confirms Phase 2 results, retatrutide could exceed the weight loss seen with tirzepatide while adding direct hepatic benefits. For men whose primary issue is metabolic dysfunction and liver fat, the triple mechanism is more aligned with the underlying physiology than dual agonism alone.